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Córdoba and Las Palmas de Gran Canaria, SpainObjectives The goal of this study was to assess the immediate and long-term outcomes in patients
undergoing percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) in an unprotected
distal left main coronary artery (UDLM).
Background PCI for UDLM-ISR can be complex. Limited information is available on procedural and
clinical outcomes.
Methods Between May 2002 and February 2011, UDLM-ISR after drug-eluting stent implantation
was observed in 79 of 1,102 patients (7%). Seventy-ﬁve were treated by repeat PCI using a simple
approach (balloon/in-stent implantation) or a complex strategy (additional stent/double-stenting
technique). A diagnosis of mild or severe restenosis was considered depending on the number of
bifurcation segments affected (1 vs. >1). Major adverse cardiac events (MACE) were deﬁned as cardiac
death, target lesion revascularization, and myocardial infarction.
Results ISR treatment was performed using a simple approach in 44 (58%) patients, and using a
complex strategy in 31 (42%). After 46  26 months, the MACE rate was 22%. Patients treated with
a simple approach had a lower incidence of MACE at follow-up compared with patients treated with
a complex strategy, regardless of the restenosis extent (mild restenosis: 93% vs. 67%, p < 0.05; severe:
70% vs. 23%, p < 0.05). On Cox regression analysis, diabetes was the only predictor of MACE (hazard
ratio [HR]: 4.94; 95% conﬁdence interval [CI]: 1.03 to 23.70; p < 0.05), whereas a simple strategy for ISR
treatment was associated with lower risk (HR: 0.25; 95% CI: 0.08 to 0.79; p ¼ 0.02).
Conclusions PCI for UDLM-ISR is safe and feasible, with a high rate of procedural success and an
acceptable long-term MACE rate. A simple strategy, when applicable, appears to be a good treatment
option, associated with a lower event rate at follow-up. (J Am Coll Cardiol Intv 2014;7:212–21)
ª 2014 by the American College of Cardiology FoundationFrom the *Department of Cardiology, Reina Soﬁa Hospital, University of Córdoba (IMIBIC), Córdoba, Spain; and the
yDepartment of Cardiology, Dr. Negrin Hospital, University of Las Palmas, Las Palmas de Gran Canaria, Spain. Dr. Pan has been
a consultant to Cordis/Johnson & Johnson. All other authors have reported that they have no relationships relevant to the contents
of this paper to disclose.
Manuscript received March 26, 2013; revised manuscript received May 30, 2013, accepted June 6, 2013.
Abbreviations
and Acronyms
CI = conﬁdence interval
DES = drug-eluting stent(s)
HR = hazard ratio
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213The use of drug-eluting stents (DES) has become wide-
spread for the percutaneous coronary intervention (PCI) of
an unprotected distal left main coronary artery (UDLM),
and it may be an alternative to coronary artery bypass graft
surgery (1–10). However, the risk of restenosis in this subset
of lesions could pose a limitation. Unprotected left main
PCI and the location of the bifurcation lesion have been
reported as predictors of restenosis after DES implantation,
with an increased incidence when both conditions are pre-
sent (11–16).
Repeat PCI in UDLM can be more complex. Further-
more, limited information is available regarding the optimal
revascularization strategy and clinical outcomes in this
particular type of patient.
The present study aimed to analyze the management,
immediate angiographic results, and long-term clinical out-
comes, as well as to evaluate the outcomes of the different
treatment strategies, in patients undergoing PCI for in-stent
restenosis (ISR) in cases with a stented UDLM.IQR = interquartile range
ISR = in-stent restenosis
IVUS = intravascular
ultrasound
LAD = left anterior
descending coronary artery
LCX = left circumﬂex
coronary artery
LM = left main coronary
artery
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
POBA = plain old balloon
angioplasty
TLR = target lesion
revascularization
UDLM = unprotected distal
left main coronary arteryMethods
Patients. Between May 2002 and February 2011, 1,102
consecutive patients with all types of Medina bifurcation le-
sions (17) involving the UDLM were treated with DES in 2
high-volume centers. Figure 1 shows the ﬂow chart of the
study. Patients were angiographically re-evaluated when
symptoms or signs of ischemia occurred. At follow-up, 79
patients presented with signiﬁcant ISR (>50% diameter
stenosis) affecting the left main coronary artery (LM), left
circumﬂex coronary artery (LCX), or left anterior descending
coronary artery (LAD). A retrospective analysis was per-
formed in the subgroup of 75 patients with UDLM-ISR
treated with repeat PCI. At least 2 years of clinical follow-up
beyond the documentation of UDLM-ISR treatment was
required for inclusion.
Patients with protected distal LM disease (deﬁned as the
presence of at least 1 patent graft to the left coronary artery),
patients treated with a precise adjustment of the stent in
the LCX or LAD ostium, and patients with a contraindi-
cation to 1 year of dual antiplatelet therapy were excluded
from this study.
Written informed consent was obtained from all patients.
First procedure. The baseline bifurcation anatomy was
assessed according to the Medina classiﬁcation (17). The
main vessel was always considered the LM into the LAD,
and the side branch was the LCX artery. The technique for
stent implantation was provisional stenting that has been
described previously (18). Pre-dilation of the side branch
was at the discretion of the operator. After LM stent im-
plantation, a kissing balloon or single side-branch post-
dilation was performed if stenosis 50% of the LCX ostium
remained or a coronary TIMI (Thrombolysis In MyocardialInfarction) ﬂow grade <3 occurred. Stenting of the side
branch was only considered in cases with suboptimal
angiographic results after side-branch ballooning. The use
of a kissing balloon was mandatory when a complex tech-
nique was performed. Angiographic re-evaluation was
strongly recommended when symptoms or silent ischemia
was observed.
Index procedure. According to the extension of the reste-
nosis, 2 types of restenosis complexity were deﬁned: mild
restenosis affecting only 1 bifurcation segment, and severe
restenosis if more than 1 bifurcation segment was affected,
regardless of the degree of lesion severity. The angiographic
patterns of restenosis were classiﬁed as focal (Mehran
ISR pattern I), diffuse (Mehran
patterns II and III), or occlusion
(Mehran pattern IV) (19).
Multifocal restenosis was con-
sidered as diffuse.
The type of treatment of the
UDLM-ISR and the technique
used were at the discretion of the
operator. Four modalities for ISR
treatment were used: 1) plain
old balloon angioplasty (POBA);
2) in-stent implantation; 3) 1 ad-
ditional stent implantation in a
segment that was not previously
stented (complex approach per-
formed in 2 stages); and 4) a 2-
stenting technique.Theﬁrst 2were
considered simple approaches, and
the other 2 were considered com-
plex strategies.
In cases requiring a new stent,
a different type of DES from the
1 implanted in the ﬁrst proce-
dure was usually chosen (20).
The operators were encouraged
to perform an intravascular ul-
trasound (IVUS) study to assess
the mechanism of ISR and the
result after PCI.
At the time of PCI, all patients were on double anti-
platelet therapy, which was continued in all patients for at
least 12 months. During the procedure, patients received
unfractionated heparin. The use of glycoprotein IIb/IIIa
inhibitors, as well as the use of intra-aortic balloon pump,
was left to the operator’s discretion.
Serial determinations of the troponin I and creatine kinase
levels were performed before and every 6 h after the proce-
dure for the ﬁrst 24 h.
Study objectives. The primary study objective was to analyze
the occurrence of major adverse cardiac events (MACE)
in patients with UDLM-ISR treated by PCI and for at least
Figure 1. Study Flow ChartdOverall Study Proﬁle
CABG ¼ coronary artery bypass graft; DES ¼ drug-eluting stents; LM ¼ left main coronary artery; PCI ¼ percutaneous coronary intervention; TLR ¼ target lesion
revascularization.
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2142 years of clinical follow-up. MACE were deﬁned as
cardiac death, myocardial infarction (MI), and target lesion
revascularization (TLR). MI and stent thrombosis were
deﬁned according to the Academic Research Consortium
criteria (21).
After the treatment of UDLM-ISR, the patients were
monitored closely by scheduled visits and phone calls (at 1
month, every 6 months for the ﬁrst 2 years, and annually
thereafter). A new cardiac catheterization was recommended
in the presence of clinical recurrence.
Statistical analysis. Continuous variables are expressed as
mean  SD or median (interquartile range [IQR]) and were
compared using the Student t test or the Mann-Whitney
U test. Categorical variables are presented as counts and
percentages and were compared using the chi-square test or
the Fisher exact test, as appropriate. TLR- and MACE-free
survival were analyzed by the Kaplan-Meier method, and
differences between groups were analyzed with the log-rank
test. Independent predictors of long-term follow-up
MACE were analyzed using Cox proportional hazards
regression models. Variables with a p value 0.1 in uni-
variate analyses were introduced into a multivariate Cox
regression model. A value of p < 0.05 was considered
statistically signiﬁcant. Statistical analyses were performed
with SPSS version 20.0.0 software (IBM, Armonk,
New York).Results
Baseline clinical, angiographic, and procedural data at the
ﬁrst procedure. From a total of 1,102 patients with UDLM
disease treated percutaneously, 606 had an angiogram at
follow-up. Clinically-driven TLR occurred in 79 (7%) pa-
tients, and 75 of these were treated with repeat PCI. The
remaining 4 patients underwent surgery (Fig. 1).
All patients were treated with DES. Sirolimus-eluting
stents were the most often implanted (41%). A single-stent
strategy across the LCX was the technique used in the
majority of patients (87%), whereas a complex technique was
required in 10 patients (13%). Approximately 68% of the
patients had additional vessel involvement beyond UDLM
disease that required PCI.
Glycoprotein IIb/IIIa was used in 11% of patients.
Clinical, angiographic, and procedural data of the patients with
ISR. The clinical, angiographic, and procedural characteristics
of the 75 patients with UDLM-ISR treated with PCI are
summarized in Table 1. The mean age was 65  11 years.
Most patients weremale (n¼ 63, 84%), and 49%had diabetes.
The mean time from ﬁrst treatment to the diagnosis of
ISR was 14  16 months (median 9 months, IQR: 6 to 16
months). In more than 25% of cases, restenosis occurred in
the ﬁrst 7 months, whereas in nearly 70% of cases, it
occurred in the ﬁrst year after UDLM treatment.
Table 1. Baseline Clinical, Angiographic, and Procedural Characteristics
of Patients With ISR
First Procedure
(n ¼ 79)*
Index Procedure
(n ¼ 75)y
Clinical
Age, yrs 64  11 65  11
Male 66 (83) 63 (84)
Currently smoking 15 (19) 10 (13)
Hypercholesterolemia 35 (44) 33 (44)
Hypertension 37 (47) 34 (45)
Diabetes 40 (51) 37 (49)
Clinical presentation
Stable angina 11 (14) 17 (23)
Unstable angina 49 (62) 49 (65)
Acute myocardial infarction 15 (19) 4 (5)
Silent myocardial ischemia 4 (5) 5 (7)
Angiographic
LV ejection fraction, % 54  14 51  12
Medina classiﬁcation
1,1,1 42 (53) 10 (13)
1,1,0 19 (24) 4 (5)
1,0,1 11 (14) 11 (15)
0,1,1 3 (4) 4 (5)
1,0,0 0 13 (18)
0,1,0 3 (4) 10 (13)
0,0,1 1 (1) 23 (31)
Main vessel reference, mm 3.7  0.3 d
Side branch reference, mm 2.8  0.3 d
Minimal lumen diameter, mmz 0.71  0.3 0.71  0.4
Procedural
Main vessel stent diameter 3.5  0.2 3.4  0.4
Maximal pressure, atm 16  2 18  3
Bifurcation treatment
Simple 69 (87) 44 (58)
Complex 10 (13) 31 (42)
Type of stent
Sirolimus 32 (41) 18 (24)
Paclitaxel 26 (33) 25 (33)
Everolimus 20 (25) 20 (27)
Zotarolimus 1 (1) 12 (16)
Lesions treated at remote sites 54 (68) 28 (37)
IVUS 57 (72) 59 (79)
IABP 4 (5) 7 (9)
Values are mean  SD or n (%). *Patients who presented with restenosis at follow-up. yPatients
with restenosis treated percutaneously. zAt the worst point of the 3 segments.
IABP ¼ intra-aortic balloon pump; ISR ¼ in-stent restenosis; IVUS ¼ intravascular ultrasound;
LV ¼ left ventricular.
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215Restenosis was located in the main vessel (LM-LAD)
in 25 patients (33%). The isolated ostial LCX was affected
in 24 (32%), and restenosis involved both vessels in the
remaining 26 patients (35%). The angiographic pattern of
restenosis was focal in 35 patients (47%), diffuse in 38 (51%),
and total occlusion of the side branch in 2 patients (2%).
An IVUS study was conducted in 59 (79%) patients.
In 8 (14%) of them, stent underexpansion was the mainmechanism of restenosis, whereas drug failure was identiﬁed
in 51 (83%) patients.
A simple approach for ISR treatment was used in most of
the patients (n ¼ 44, 58%): POBA was performed in 13
(17%), and in-stent implantation in 31 (41%) patients.
POBA was the deﬁnitive treatment in 5 (38%) patients with
focal restenosis of the circumﬂex coronary artery and in
8 (62%) with stent underexpansion by IVUS. Conversely,
a complex strategy was used in the remaining 31 (42%)
patients: 1 additional stent implantation in 22 (30%), and a
2-stent implantation in 9 (12%). Figure 2 shows the location
of restenosis according to the Medina classiﬁcation and the
treatment modality used in each case.
In-hospital and long-term clinical follow-up MACE. During
the hospital stay, 2 patients suffered a non–Q-wave MI, and
3 (4%) died: 2 of heart failure despite successful angio-
graphic results, and another patient of cardiogenic shock
after LM MI (1 probable stent thrombosis).
The long-term follow-up data were available in 100% of
patients after an average of almost 4 years after ISR treat-
ment. The overall MACE rate at the long-term follow-up
(mean 46  26 months, median 39 months, IQR: 24 to 64
months) was 22%. Six patients (8%) died from cardiac
causes (3 from sudden death, 2 from heart failure, and 1
from inferior MI), and 3 (4%) had a nonfatal MI. Nine of
10 patients who required a new revascularization were
treated again by PCI. We identiﬁed 3 cases of possible stent
thrombosis. No cases of deﬁnite or probable stent throm-
bosis were found.
Figure 3 shows survival free from TLR and MACE ac-
cording to the complexity of the UDLM-ISR. MACE-free
survival was signiﬁcantly higher in patients undergoing ISR
affecting only 1 bifurcation segment compared with patients
with more than 1 segment involved (84% vs. 47%; p < 0.05).
The inﬂuence of the modality of ISR treatment on the
results at the long-term follow-up was also analyzed. No
clinical or angiographic differences were found between
patients treated with simple or complex strategies (Table 2).
Patients treated with only POBA or with in-stent implan-
tation, that is, with a simple approach, had a lower incidence
of events at follow-up compared with patients undergoing a
complex approach, including TLR (event-free survival 97%
vs. 63%; p < 0.05) and MACE (85% vs. 53%; p < 0.05)
(Fig. 4). To determine whether this ﬁnding was related to
the complexity of the ISR, the patients were divided into 2
groups according to the type of ISR (as previously deﬁned),
and similar results were obtained. Figure 5 depicts the event-
free survival in patients with ISR affecting only 1 bifurcation
segment in relation to the type of the treatment used. The
event incidence was clearly lower in patients treated with a
simple strategy (TLR-free survival 96% vs. 67%, p < 0.05;
MACE-free survival 93% vs. 67%, p < 0.05). The same
results were found when analyzing the inﬂuence of the
treatment in patients with ISR affecting more than 1
Figure 2. Location of Restenosis According to the Medina Classiﬁcation and the Treatment Modality Used in Each Situation
(A) Patients treated at the ﬁrst procedure by a simple approach. (B) Patients treated at the ﬁrst procedure by a complex strategy.
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216bifurcation segment (TLR-free survival 100% vs. 50%, p <
0.05; MACE-free survival 70% vs. 23%, p < 0.05) (Fig. 6).
Predictors of MACE at follow-up. The multivariate predictors
of overall MACE are shown in Table 3. Diabetes was the
only independent predictor of MACE (hazard ratio [HR]:
4.94; 95% conﬁdence interval [CI]: 1.03 to 23.70; p < 0.05),
whereas ISR treatment using a simple strategy was inde-
pendently associated with a lower risk of MACE at thelong-term follow-up (HR: 0.25; 95% CI: 0.08 to 0.79;
p ¼ 0.02).
Discussion
Since the introduction of DES, a growing number of
observational studies and randomized clinical trials have
supported their safety and efﬁcacy in the percutaneous
Figure 3. Event-Free Survival Following the Extension of Restenosis
The survival rates for 1 segment versus more than 1 segment affected are shown. (A) Target lesion revascularization. (B) Major adverse cardiac events.
Table 2. Baseline Clinical, Angiographic, and Procedural Characteristics of Patients According to the
Treatment Strategy at the Index Procedure
Simple Approach
(n ¼ 44)
Complex Approach
(n ¼ 31) p Value
Clinical
Age, yrs 66  10 64  12 NS
Male 34 (77) 29 (93) 0.06
Currently smoking 6 (14) 4 (13) NS
Hypercholesterolemia 17 (39) 16 (52) NS
Hypertension 18 (41) 16 (52) NS
Diabetes 23 (52) 14 (45) NS
Clinical presentation
Stable angina 10 (23) 7 (22)
Unstable angina 28 (64) 21 (68)
Acute myocardial infarction 2 (4) 2 (6) NS
Silent myocardial ischemia 4 (9) 1 (3)
Angiographic
LV ejection fraction, % 51  13 52  13 NS
Extension of restenosis
1 bifurcation segment affected 29 (64) 16 (36) NS
More than 1 segment affected 15 (50) 15 (50)
Main vessel diameter, mm 3.6  0.2 3.7  0.4 NS
Side branch diameter, mm 2.7  0.2 2.8  0.3 NS
*Minimal lumen diameter, mm 0.65  0.38 0.69  0.31 NS
Procedural
Main vessel stent diameter 3.4  0.2 3.5  0.3 NS
Maximal pressure, atm 17  3 16  2 NS
Type of stent previously used
Sirolimus 18 (41) 13 (42)
Paclitaxel 16 (36) 10 (32) NS
Everolimus 10 (23) 8 (26)
IVUS 35 (79) 24 (77) NS
Values are mean  SD or n (%). *At the worst point of the 3 segments.
NS ¼ non statistically signiﬁcant; other abbreviations as in Table 1.
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Figure 4. Event-Free Survival According to the Restenosis Treatment Modality in the Global Series
(A) Target lesion revascularization. (B) Major adverse cardiac events.
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218treatment of UDLM. Nevertheless, ISR in this subset of
lesions represents an increasing problem in daily practice,
and currently, there is insufﬁcient information to determine
the best treatment option (3,14,22–25).
In the present study, which includes 75 patients with
UDLM-ISR from 1,102 patients with LM bifurcation
treated percutaneously with DES, we found that repeat PCI
was safe and feasible at 4-year clinical follow-up and may be
a good option for treatment. In our registry, in which almost
90% of the patients were treated by provisional stenting atFigure 5. Event-Free Survival According to the Restenosis Treatment Modality in
Medina classiﬁcation of the bifurcation lesions (1, 0, 0), (0, 1, 0), and (0, 0, 1) are shothe ﬁrst procedure, ISR treatment with the same strategy
(simple approach) was associated with a lower occurrence of
MACE at the long-term follow-up as compared with a
complex treatment strategy.
The clinically-driven TLR rate in our series was overall
low (7%). This fact could be explained by the high rate of
patients treated by a simple approach at the ﬁrst procedure
and the absence of routine angiographic follow-up
(13,26,27). It is known that 2-stent techniques are associ-
ated with less favorable outcomes when a bifurcation lesionPatients With Restenosis Affecting Only 1 Bifurcation Segment
wn. (A) Target lesion revascularization. (B) Major adverse cardiac events.
Figure 6. Event-Free Survival According to the Restenosis Treatment Modality in Patients With Restenosis Affecting More Than 1 Bifurcation Segment
Medina classiﬁcation of the bifurcation lesions (1, 1, 0), (1, 0, 1), (0, 1, 1), and (1, 1, 1) are shown. (A) Target lesion revascularization. (B) Major adverse cardiac events.
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219is treated. Although some patients with UDLM and com-
plex anatomy could require 2 stents, our large series of pa-
tients treated demonstrates that a simple approach would be
suitable for the majority of these patients.
The incidence, management, predictors, and prognosis of
patients with UDLM-ISR after DES implantation have
been studied in previous studies. Sheiban et al. (28) and Lee
et al. (29) studied approximately 70 patients with restenosis,
analyzing 3 types of treatment: medical therapy, repeat PCI,
and coronary artery bypass graft surgery. Although both
studies provide valuable information, neither of them
focused on UDLM with its special feature, characteristic
regarding risk of restenosis and percutaneous treatment. In
contrast to the present registry, their objective was to assess
the 3 possible treatments stated in the preceding text.
Consequently, details about different percutaneous strategies
were not reported. The small size of the groups did not allow
the detection of signiﬁcant differences among them.
To the best of our knowledge, the only study published to
date focusing on UDLM and on PCI for restenosis treat-
ment is the MITO (Milan and New-Tokyo) registry (30).Table 3. Univariate and Multivariate Predictors of MACE a
Univariable HR (
Age 70 yrs 2.20 (0.89–5.
EF <45% 3.63 (1.35–9.
Diabetes mellitus 3.05 (1.00–9.
Restenosis extension: 1 bifurcation segment 0.31 (0.12–0.
Treatment strategy: simple approach 0.30 (0.12–0.
CI ¼ conﬁdence interval; EF ¼ ejection fraction; HR ¼ hazard ratio; MACEOf 474 patients with UDLM involvement, 92 developed
restenosis, and 84 (19%) were treated with repeat PCI (43
with POBA and 41 with further DES implantation). They
found that the majority of patients with focal LCX reste-
nosis were asymptomatic, and the POBA strategy resulted in
signiﬁcantly more recurrence than the use of DES (HR:
4.14; 95% CI: 1.21 to 14.25; p ¼ 0.02). These ﬁndings are
contradictory to those reported by us, given that we observed
that POBA provided excellent results at follow-up in cases
of focal LCX restenosis and when stent underexpansion (by
IVUS) was the main mechanism of restenosis. Differences in
clinical and procedural characteristics between the study
population in the 2 studies could explain the different re-
sults. In the MITO registry (30), the number of patients
treated at the ﬁrst procedure with a complex strategy was
higher (58%) than in our series (13%), and this fact could
have inﬂuenced the results observed with the following
different strategies of percutaneous treatment. On the other
hand, the use of POBA was high in this study (51% of the
patients), and the criteria for choosing each treatment are
not speciﬁed. Probably, POBA does not work properly in allt Follow-Up
95% CI) p Value
Cox Regression
Adjusted HR (95% CI) p Value
49) 0.1
78) 0.01
28) 0.05 4.94 (1.03–23.70) 0.046
78) 0.014
78) 0.013 0.25 (0.08–0.79) 0.02
¼ major adverse cardiac events.
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220of the mechanisms of restenosis and should be used only in
particular cases.
Regarding the best alternative to treat this speciﬁc group of
patients, we found that a simple approach (POBA and/or in-
stent implantation) was correlated with a lower TLR and
MACE as compared with a complex strategy. This ﬁnding
has to be put in context of the treatment used at the ﬁrst
procedure and is concordant with previous studies in native
bifurcation reporting the clinical advantages of provisional
stenting compared with double-stenting techniques (31).
Accordingly, Coroleu et al. (32), in a recently published study
on percutaneous treatment for the in-stent restenosis of
bifurcated lesions, have also demonstrated a lower incidence
of MACE in patients treated with a provisional single DES
implantation. Therefore, it appears that restenotic lesions in
bifurcated locations should be approached as native bifurca-
tion lesions when applicable, for which provisional stenting
is considered the choice technique.
Study limitations. This was an observational, non-
randomized study. The restenosis treatment modality was
left to the operator’s discretion, and therefore, no deﬁnitive
conclusions on the best technique for the ISR treatment of
the DLM can be drawn from our study. Nevertheless, the
absence of signiﬁcant differences between patients treated
with simple and complex strategies, as well as the multi-
variate analyses, support the simple approach as the most
suitable treatment option. The number of patients included
was relatively small, but because of the low rate of restenosis,
it was difﬁcult to obtain a large sample size. Furthermore,
the small event rate can reduce the ability to control
potentially confounding variables. Finally, drug-eluting
balloons were not available in our institutions at the time
that the patients were treated. Although these balloons can
play an important role in this subset of lesions, their use
would have to be evaluated.Conclusions
Our study shows that the incidence of clinically-driven TLR
in an unselected population of patients with UDLM after
DES implantation is low. Treatment with repeat PCI in this
subset of lesions appears to be safe and effective, with a high
rate of angiographic and procedural success and an accept-
able long-term MACE rate. Our ﬁndings also suggest that
a simple strategy in the ISR approach is correlated with
lower TLR and consequently MACE as compared with a
more complex approach. Further randomized studies will be
necessary to conﬁrm these results.
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